Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-55~* Relapsing-Remitting Multiple Sclerosis (RRMS)~* Avonex therapy for 6 months prior continuous~* annualized relapse rate \>2 during Avonex therapy~* most recent relapse within 60 days of baseline~* entry Expanded Disability Status Scale (EDSS) 1.5-4.5~* one or more gadolinium (Gd+) MRI lesions on a baseline MRI~* no history of immune modulator or immunosuppressant therapy used in combination with Avonex (other then GSC administer for clinical relapses)~* not participating in any other study of ms therapeutics~* Serum neutralizing antibodies (NABs) titer to Avonex \<20~Exclusion Criteria:~* Medical or Psychiatric conditions that will affect patients ability to provide informed consent~* inability to undergo MRI~* clinically serious medical conditions or significantly abnormal labs~* no use of these medications or procedures within six months prior to study:~  \*monoclonal antibodies,total lymphoid radiation,systemic steroids,cytotoxic or immunosuppressive medications such as mitoxantrone or cyclophosphamide or any other investigational drugs~* Interferon neutralizing antibody titers \>20~* no breast feeding or pregnant~* no patients with any systemic illness,psychiatric condition or other disorder that would concern safety of patient to complete procedures of protocol~* abnormal blood test~* clinically significant abnormality on chest x-ray (CXR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Interferon beta 1a, oral doxycycline

Based on this trial design, predict the completion outcome and termination type (if applicable).